As the world’s largest grassroots network of breast cancer survivors and activists, Susan G. Komen for the Cure is working to save lives, empower people, ensure quality care for all and energize science to find the cures. In furthering this mission, the goal of the organization is to create a community of individuals, communities, and corporations to spread life saving messages and to raise funds to support the cause of ending breast cancer forever.
We value our corporate partners and the role they play in our fight. At the same time, we recognize that transparency regarding how we engage with these partners is important to maintain the integrity of our organization and to ensure all of our constituents understand our financial and organizational stewardship. As a result, our organization has promulgated the following corporate engagement policy:
Corporate Engagement Philosophy
Subject to limitations provided herein, Susan G. Komen for the Cure accepts funding from corporations for research, educational and community outreach programs, public policy, international programs, and general operations. We are committed to responsible engagement with corporations in keeping with our mission, and compliance with all rules and regulations to promote ethical and transparent business arrangements.
Selection of Corporate Partners
Corporate relationships must have a meaningful mission-related benefit to the general public or to particular constituencies of Susan G. Komen for the Cure.
Susan G. Komen for the Cure does not endorse any medical product or treatment, or any specific feature or attribute of any product sold by a corporate partner of the organization. Nothing in this policy, however, shall limit the ability of the organization’s Scientific Advisory Board from opining on the efficacy of therapies for the prevention or treatment of breast cancer and associated issues.
Susan G. Komen for the Cure shall make best efforts to have a written agreement for each of its corporate engagements. Such agreement will detail the parameters of the use of the organization’s name and/or logo, and will require that the corporate partners comply with all applicable laws and regulations.
While the value of the pharmaceutical industry in helping to discover and deliver the cures for breast cancer is unquestionable, pharmaceutical funding is required to be limited to a small percentage of the organization’s operating budget, and pharmaceutical funding may not be directed to the funding of specific scientific research or specific public policy initiatives. In addition, safeguards are in place to ensure that pharmaceutical funding will not directly influence the content of patient education.
Conflicts of Interest and Whistleblower Policy
The Board of Directors, Scientific Advisory Board, staff and certain volunteers and participants in our granting process are required to disclose potential conflicts of interest, including substantial ownership in corporate entities. Any potential conflicts are reviewed and addressed at least annually by the Audit Committee of the Board of Directors. In addition, the organization maintains a Whistleblower Policy, providing an anonymous mechanism for any internal and external reports of organizational irregularity.
Disclosure of Corporate Funding
Susan G. Komen for the Cure discloses all corporate funding in its financial filings, which are available to the general public.